The underlying pathological processes resulting in AP overactivation are not completely understood yet, though mutations in the genes of the AP components or autoantibodies targeting these proteins were described in some cases of MPGN [21,23,24,38,48,49,50,51]. This evidence concerns the gene DHCR7-DT and primary membranoproliferative glomerulonephritis.